ArticleeLife2025
Peripheral opioid receptor antagonism alleviates fentanyl-induced cardiorespiratory depression and is devoid of aversive behavior.
Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A Wireless Wearable Platform for Intravenous Drug Self-Administration in Freely Behaving Rats.bioRxiv : the preprint server for biology · 2026Article
- Hypothalamic Glutamatergic/Orexinergic Neurons Attenuate Fentanyl-Induced Respiratory Depression via Medullary Pre-BöTzinger Complex Pathways.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.Psychopharmacology · 2026Article
- Dermorphin blocks apneic response to intravenous bolus injection of fentanyl.Toxicology and applied pharmacology · 2026Article
- Acute buprenorphine exposure depresses neonatal respiratory chemoreflexes in the presence or absence of naloxone.bioRxiv : the preprint server for biology · 2026Article
- Fentanyl decreases blood oxygen more than furanylfentanyl despite similar effects on breathing.Research square · 2026Article
- The role of central versus peripheral opioid receptors in fentanyl-induced brain hypoxia.Journal of neurophysiology · 2026Article
- Roles of peripheral and central µAmerican journal of physiology. Lung cellular and molecular physiology · 2025Article
- Searching for Synthetic Opioid Rescue Agents. 2: Identification of an Ultra-Potent Synthetic Opioid Rescue Agent.Journal of medicinal chemistry · 2025Article
- Estradiol protects against pain-facilitated fentanyl use via suppression of opioid-evoked dopamine activity in males.Neuron · 2025Article
- Finding new ways to treat overdoses.eLife · 2025Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Millions of Americans suffering from Opioid Use Disorders face a high risk of fatal overdose due to opioid-induced respiratory depression (OIRD). Fentanyl, a powerful synthetic opioid, is a major contributor to the rising rates of overdose deaths. Reversing fentanyl overdoses has proved challenging due to its high potency and the rapid onset of OIRD. We assessed the contributions of central and peripheral mu opioid receptors (MORs) in mediating fentanyl-induced physiological responses. The peripherally restricted MOR antagonist naloxone methiodide (NLXM) both prevented and reversed OIRD to a degree comparable to that of naloxone (NLX), indicating substantial involvement of peripheral MORs to OIRD. Interestingly, NLXM-mediated OIRD reversal did not produce aversive behaviors observed after NLX. We show that neurons in the nucleus of the solitary tract (nTS), the first central synapse of peripheral afferents, exhibit a biphasic activity profile following fentanyl exposure. NLXM pretreatment attenuates this activity, suggesting that these responses are mediated by peripheral MORs. Together, these findings establish a critical role for peripheral MORs, including ascending inputs to the nTS, as sites of dysfunction during OIRD. Furthermore, selective peripheral MOR antagonism could be a promising therapeutic strategy for managing OIRD by sparing CNS-driven acute opioid-associated withdrawal and aversion observed after NLX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.